1OP has a strong strategy on expanding the patent portfolio around its lead compound, 1OP-2198, an IND-ready small molecule potassium channel opener for Kv7 (KCNQ) ion channels, for unmet and orphan CNS hyperexcitability-related disorders in neurology and pain. Due to the uniqueness and breadth of the pharmacological target, Kv7-relevant indications for modulation of neuronal activity that may be relevant for 1OP-2198 include the following:

  • Breakthrough pain
  • General acute pain
  • Epilepsy
  • Chronic musculoskeletal pain
  • Neuropathic pain
  • Acute optic neuritis
  • Dyskinesia/Dystonia
  • Anxiety/Depression/Migraine
  • Tinnitus